Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of “Hold” from Analysts

Moderna, Inc. (NASDAQ:MRNA) has been given an average recommendation of “Hold” by the twenty-three brokerages that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $41.8125.

Several brokerages recently weighed in on MRNA. Leerink Partners dropped their target price on Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a report on Friday, August 22nd. Barclays dropped their target price on Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a report on Monday, August 4th. Cowen initiated coverage on Moderna in a report on Sunday, July 13th. They set a “hold” rating for the company. Citigroup initiated coverage on Moderna in a report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price objective for the company. Finally, Bank of America dropped their price objective on Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a report on Tuesday, July 22nd.

Moderna Price Performance

Shares of MRNA stock opened at $27.92 on Thursday. The stock has a market capitalization of $10.90 billion, a PE ratio of -3.71 and a beta of 2.01. Moderna has a 1-year low of $23.15 and a 1-year high of $59.73. The business has a 50-day moving average of $25.98 and a 200 day moving average of $27.30.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna’s quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Analysts anticipate that Moderna will post -9.61 EPS for the current year.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the business. Parkside Financial Bank & Trust lifted its holdings in Moderna by 19.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock worth $65,000 after buying an additional 375 shares during the period. Probity Advisors Inc. lifted its holdings in Moderna by 2.6% in the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock worth $411,000 after buying an additional 377 shares during the period. Deseret Mutual Benefit Administrators lifted its holdings in Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock worth $32,000 after buying an additional 392 shares during the period. Amalgamated Bank lifted its stake in shares of Moderna by 0.6% in the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock valued at $1,806,000 after purchasing an additional 408 shares during the period. Finally, Rothschild Investment LLC lifted its stake in shares of Moderna by 94.1% in the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after purchasing an additional 446 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.